Results 111 to 120 of about 22,249,811 (294)
Light-Activated Azobenzene Peptide Inhibitor of the PD-1/PD-L1 Interaction
Inhibiting the protein-protein interaction between programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) has become a focal point in immunotherapy for cancer treatments.
Deanne, Hayward +4 more
core +1 more source
, 2019 Additional file 1: Figure S1. In vivo Scheme of treatment. A. Scheme of treatment for syngeneic murine models: Peptide R was intraperitoneally administered 5 day/week for 2, Anti-PD-1 was intraperitoneally administered at Day 1–4–7-10-13. B.
Caterina Ieranò (458554) +18 more
core +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
, 2019 Context: As a special stage in type 1 diabetes (T1D), partial remission (PR) is accompanied by downregulation of the immune response. Programmed cell death-1 (PD-1) and its ligand (PD-L1) are important immunosuppressive molecules, and their changes in ...
Yuting Xie (8197720) +6 more
core +1 more source
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
, 2019 Aim: To determine if silencing PD-1 on tumor-infiltrating lymphocytes (TILs) and its ligand-1 (PD-L1) on cancer cells will enhance the cytotoxicity of TILs.
Chen, Chen +4 more
core +1 more source
PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
Frontiers in ImmunologyProgrammed cell death protein 1 (PD-1) is an immune checkpoint molecule until recently believed to exist only in tetrapod species. However, together with a very recent study dedicated to the CD28/CTLA4 molecule family, this study—using database ...
Ryohei Kondo +6 more
doaj +1 more source
PD-1/PD-L1 Inhibitors in Cervical Cancer
Frontiers in Pharmacology, 2019 Cervical cancer is one of the most common gynecological tumors, and the majority of early-stage cervical cancer patients achieve good recovery through surgical treatment and concurrent chemoradiotherapy (CCRT).
Yuncong Liu +14 more
doaj +1 more source
A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance
Frontiers in Cell and Developmental Biology, 2020 In recent years, as our understanding of tumor immunology is continuously improved, immunotherapy has come to the center stage of cancer therapy and is deemed as the most promising approach for cancer control.
Qian Huang +4 more
doaj +1 more source
Molecular Oncology, EarlyView.Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi +14 more
wiley +1 more source